Antifolate Linker-Drug Conjugates for Targeted Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antifolate drugs, such as methotrexate, pemetrexed, pralatrexate, and talotrexin, have limited target specificity and cause adverse effects on both cancer cells and normal cells due to their non-specific action, leading to mediocre to poor efficacy in antibody-drug conjugates (ADCs) for treating cancer, autoimmune, and infectious diseases.
Innovation Solution
Development of novel antifolate linker-drugs conjugated to antibodies or antigen-binding fragments, which are designed to specifically target cancer cells by using a linker moiety that can be conjugated to antibodies, allowing for controlled release of the antifolate compound, thereby reducing toxicity and improving efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antifolate drugs are used, then broad antiproliferative activity is achieved, but target specificity is poor and adverse effects on non-target tissues occur
Solution Approach 1:
The invention divides the therapeutic system into two distinct components: a targeting molecule (antibody or antigen-binding fragment) and a cytotoxic antifolate agent. The antibody specifically binds to tumor-associated antigens, while the antifolate provides the cytotoxic effect. This segmentation allows the targeting function and cytotoxic function to be optimized independently and combined through conjugation, thereby achieving high target specificity while minimizing adverse effects on non-target tissues.
Solution Approach 2:
The invention introduces a linker as an intermediary component that connects the antibody to the antifolate agent. This linker serves as a mediator that enables controlled delivery of the cytotoxic agent to the target site. The linker can be designed to be stable in circulation but cleavable at the target site, providing precise spatial and temporal control over drug release, thereby enhancing target specificity and reducing off-target toxicity.
2Reliability
If antibody-drug conjugates are developed, then target specificity is improved, but efficacy remains mediocre to poor
Solution Approach 1:
The invention optimizes multiple parameters of the antibody-drug conjugate system, including the choice of antifolate agent (methotrexate, pemetrexed, pralatrexate, or talotrexin), the linker structure and cleavability, and the drug-to-antibody ratio. By systematically varying these parameters, the invention achieves both high target specificity and improved therapeutic efficacy, overcoming the limitations of previous ADCs with mediocre performance.
Solution Approach 2:
The invention creates a composite therapeutic agent by combining three distinct components: the antibody (targeting component), the linker (delivery component), and the antifolate agent (cytotoxic component). Each component contributes its specific function, and their synergistic combination results in an ADC with both high target specificity and superior therapeutic efficacy compared to the sum of individual components.
3Ease of operation
If non-specific antifolate action is used, then simplicity of administration is maintained, but therapeutic index is reduced due to toxicity
Solution Approach 1:
The invention performs preliminary targeting by equipping the antifolate agent with an antibody that specifically recognizes tumor cells before administration. The antibody-antifolate conjugate is designed to accumulate at the tumor site through specific binding, ensuring that the cytotoxic action occurs preferentially at the target site. This preliminary localization reduces systemic exposure and toxicity while maintaining ease of administration as a single conjugate formulation.
Data Source
AI summary
The present invention relates to novel antifolate linker-drugs, conjugates comprising such antifolate linker-drugs, and the use thereof in the treatment of diseases, such as cancer, autoimmune and infectious diseases, optionally in combination with other therapeutic agents.